Journals / Glokom Katarakt / 2017 / Cilt: 12 - Sayı: 1

Transscleral Diode Laser Cyclophotocoagulation in Glaucoma Patients With Good Visual Acuity

Görme Keskinliği İyi Olan Glokom Hastalarında Transskleral Diod Laser Siklofotokoagülasyon*

Pages
37–41
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall success was defined as a final intraocular pressure (IOP) between 7 and 21 mmHg.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the efficacy and safety of transscleral diode laser cyclophotocoagulation (TDLC) procedure in glaucoma patients with good visual acuity.
📊
Key Findings & Data:Materials and Methods: Charts of glaucoma patients underwent TDLC between January 2012 and June 2015 were reviewed retrospectively.
💡
Conclusion & Impact:Overall success was defined as a final intraocular pressure (IOP) between 7 and 21 mmHg.
🔬Design:Review & Systematic Survey
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the efficacy and safety of transscleral diode laser cyclophotocoagulation (TDLC) procedure in glaucoma patients with good visual acuity. Materials and Methods: Charts of glaucoma patients underwent TDLC between January 2012 and June 2015 were reviewed retrospectively. Eyes with a baseline Snellen best-corrected visual acuity (BCVA) of >= 20/100 with a minimum follow-up of 6 months were included. Overall success was defined as a final intraocular pressure (IOP) between 7 and 21 mmHg. Visual acuity scores, IOP levels and total number of antiglaucomatous medication was recorded. Shapiro-Wilk test and paired samples t test were used for statistics.Results: Twelve eyes of 12 patients (4 females, 8 males) were included. Mean age was 45.4±22.7 years (6 - 69) and mean follow-up was 13.8±9.0 months (6 - 35). Glaucoma diagnosis was primary open-angle glaucoma in 8 eyes (66.7%), juvenile glaucoma in 2 eyes (16.7%), aphakic glaucoma in 1 eye (8.3%) and neovascular glaucoma in 1 eye (8.3%). Pretreatment BCVA and IOP were 0.39±0.21 (20/100 - 20/30) and 29.6±5.9 mmHg (22 - 40), whereas they were found as 0.51±0.23 (20/100 - 20/25) and 17.6±4.2 mmHg (12 - 25) at the last follow-up visit (p=0.089 and p<0.001). All cases were put on 4 antiglaucomatous medication before treatment, however the mean number of antiglaucomatous medication decreased to 2.85±0.38 (2 - 3) at the final visit (p=0.001). Overall success was achieved in 9 eyes (75.0%).Conclusion: Transscleral diode laser cyclophotocoagulation is an effective IOP-lowering procedure; which can also be safely used in eyes with good visual acuity.

Özet

Amaç: Transskleral diod laser siklofotokoagülasyon (TDLS) işleminin, görmesi iyi olan glokom hastalarındaki etkinlik ve güvenilirliğinin değerlendirilmesiGereç ve Yöntemler: Ocak 2012 ile Haziran 2015 tarihleri arasında TDLS uygulanan glokom hastalarının dosyaları retrospektif olarak tarandı. Başlangıç en iyi düzeltilmiş görme keskinliği (EİDGK) Snellen eşeline göre >= 20/100 olan ve tedavi sonrası en az 6 ay süreli takibi olan gözler çalışmaya alındı. Sonuç göz içi basıncının (GİB) 7 ile 21 mmHg arasında olması tedavi başarısı olarak tanımlandı. Olguların görme keskinliği düzeyi, GİB ve toplam antiglokomatöz ilaç sayıları kaydedildi. İstatistiksel analizler için Shapiro-Wilk testi ve bağımlı gruplarda t testi kullanıldı.Bulgular: Çalışmaya 12 hastanın (4 kadın, 8 erkek) 12 gözü dahil edildi. Ortalama yaş 45.4±22.7 yıl (6 - 69 yıl) ve ortalama takip süresi 13.8±9.0 ay (6 - 35 ay) olarak bulundu. Glokom tanıları 8 gözde (%66.7) primer açık açılı glokom, 2 gözde jüvenil glokom (%16.7), 1 gözde (%8.3) afakik glokom ve 1 gözde (%8.3) neovasküler glokomdu. Tedavi öncesi EİDGK ve GİB düzeyi sırasıyla 0.39±0.21 (20/100 - 20/30) ve 29.6±5.9 mmHg (22 - 40 mmHg) iken; son takipte bu değerler 0.51±0.23 (20/100 - 20/25) ve 17.6±4.2 mmHg (12 - 25 mmHg) olarak bulundu (p=0.089 ve p<0.001). Tüm olgular tedavi öncesi 4 ilaç kullanırken, ortalama antiglokomatöz ilaç sayısı son takipte 2.85±0.38'e (2 - 3) geriledi (p=0.001). Tedavi başarısına 9 gözde (%75.0) ulaşıldı.Sonuç: Transskleral diod laser siklofotokoagülasyon etkili bir GİB düşürücü işlem olup, iyi görmeye sahip gözlerde de güvenli olarak kullanılabilir.

🔖

Cite This Article

ÖZTÜRK, A. T., ARIKAN, G., ÜNLÜ, B., GÜNENÇ, Ü. (2017). Transscleral Diode Laser Cyclophotocoagulation in Glaucoma Patients With Good Visual Acuity. Glokom Katarakt, Cilt: 12 - Sayı: 1, 37–41. https://ajindex.com/articles/226811

References (12)

  1. Garway-Heath DF, Lascaratos G, Bunce C, et al. The United Kingdom Glaucoma Treatment Study: a multicenter, randomized, placebo-controlled clinical trial: design and methodology. Opht- halmology 2013;120:68-76.
  2. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Mani- fest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.
  3. Bitirgen G, Okka M, Bozkurt B, ve ark. Dirençli glokom olgula- rında transskleral diod lazer siklofotokoagülasyon. Turk J Opht- halmol 2012;42:434-7.
  4. Aktaş Z, Ünlü M, Yüksel E, ve ark. İleri ve dirençli glokomda transskleral diyot lazer siklodestrüksiyon etkin ve güvenilir bir tedavi yöntemi mi? Glo-Kat 2011;6:97-101. Bloom PA,Tsai JC, Sharma K, et al. "Cyclodiode". Trans-scleral diode laser cyclophotocoagulation in the treatment of advanced refractory glaucoma. Ophthalmology 1997;104:1508-19; discus- sion 1519-20.
  5. Vernon SA, Koppens JM, Menon GJ, et al. Diode laser cycloab- lation in adult glaucoma: long-term results of a standard protocol and review of current literature. Clin Experiment Ophthalmol;34:411-20. Ishida K. Update on results and complications of cyclophotocoa- gulation. Curr Opin Ophthalmol 2013;24:102-10.
  6. Bloom PA, Clement CI, King A, et al. A comparison between tube surgery, ND:YAG laser and diode laser cyclophotocoagula- tion in the management of refractory glaucoma. Biomed Res Int;2013:371951.
  7. Frezzotti P, Mittica V, Martone G, et al. Longterm follow-up of diode laser transscleral cyclophotocoagulation in the treatment of refractory glaucoma. Acta Ophthalmol 2010;88:150-5.
  8. Pokroy R, Greenwald Y, Pollack A, et al. Visual loss after diode laser cyclophotocoagulation for primary open-angle and neovas- cular glaucoma. Ophthalmic Surg Lasers Imaging 2008;39:22-9.
  9. Lai JS, Tham CC, Chan JC, et al. Diode laser transscleral cyc- lophotocoagulation as primary surgical treatment for medically uncontrolled chronic angle closure glaucoma: long-term clinical outcomes. J Glaucoma 2005;14:114-9.
  10. Winkler NF, Funk J. Transscleral cyclophotocoagulation as pri- mary surgical intervention in glaucoma. Klin Monbl Augenheilkd;230:353-7.
  11. Grueb M, Rohrbach JM, Bartz-Schmidt KU, et al. Transscleral diode laser cyclophotocoagulation as primary and secondary surgical treatment in primary open-angle and pseudoexfoliative glaucoma. Long-term clinical outcomes. Graefes Arch Clin Exp Ophthalmol 2006;244:1293-9.
  12. Egbert PR, Fiadoyor S, Budenz DL, et al. Diode laser transscleral cyclo